Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease

By sjmartinez • October 21, 2022

Nee R, Yuan CM, Narva AS, Yan G, Norris KC. Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease. Nephrol Dial Transplant. 2022 Oct 20:gfac283. doi: 10.1093/ndt/gfac283. Epub ahead of print. PMID: 36264305.

Tags: cardiovascular disease, Chronic kidney disease, diabetes mellitus, glucagon-like peptide-1 receptor agonist, Nephrology, nonsteroidal mineralocorticoid receptor antagonist, Publications, sodium-glucose cotransporter-2 inhibitor

Related Posts

Nondialytic Care vs Dialysis Transition on Hospitalization: Outcomes in Veterans With Advanced Chronic Kidney Disease

Rhee CM, Narasaki Y, Crowley ST, Kovesdy CP, Mukamel DB, You AS, Nguyen M, Siu MKM, Le L, Novoa A, Nguyen DV, Kalantar-Zadeh K. Nondialytic[...]

Continuous Glucose Monitoring and Mortality Risk Among U.S. Veterans Receiving Dialysis With Diabetes

Narasaki Y, Kalantar-Zadeh K, Zisman-Ilani Y, Klonoff DC, Kovesdy CP, Li Z, Jin A, Crowley S, M Belcher J, Gee P, Gin GE, Jordan M,[...]

Racial and Ethnic Disparities in Living Donor Kidney Transplantation in California: 2010-2024

Al Ammary F, Adeyemo S, Lincoln KD, Ku E, Adey DB, Lau WL, Rhee CM, Kalantar-Zadeh K, Flores GM. Racial and Ethnic Disparities in Living[...]